Overview
TOVX market data
Price History
TOVX price chart · 1M
- O
- 0.242400
- H
- 0.244500
- L
- 0.238800
- C
- 0.243900
- Vol
- 8,406.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $0.24
- Previous Close
- $0.24
- Day High
- $0.24
- Day Low
- $0.24
- 52 Week High
- $0.49
- 52 Week Low
- $0.18
- 7 Day Return
- +5.04%
- 30 Day Return
- +12.34%
- 90 Day Return
- -22.05%
- 1 Year Return
- +9.96%
- Daily Notional Volume
- $2.1K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.96 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.19 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -681.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.16 – $0.86 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $10.6M · P/B 0.46 · P/S 35.18.
Company News
8-K filing — Theriva Biologics, Inc. (TOVX)SEC EDGAR · Aug 11, 2026, 12:10 PM
Theriva Biologics Q2 EPS $(0.07) Misses $(0.05) EstimateBenzinga · Aug 11, 2026, 12:06 PM
Theriva Biologics Doses First Patient In VIRAGE2 Phase 2a Clinical Trial, Small Proof-Of-Concept Study Evaluating More Frequent Repeated Dosing Of VCN-01 In First-Line Metastatic PDAC Patients Treated With Gemcitabine/Nab-Paclitaxel ChemotherapyBenzinga · Aug 6, 2026, 12:08 PM
Theriva Biologics Receives Spanish Agency Of Medicines And Medical Devices Authorization To Initiate Its VIRAGE2 Clinical TrialBenzinga · Jul 7, 2026, 12:15 PM
Theriva Biologics shares are trading higher after the company announced the publication of clinical, translational results from VCN-01's Phase 1 clinical trial in Head & Neck Squamous Cell Carcinoma in Clinical Cancer Research journal.Benzinga · Jun 11, 2026, 12:46 PM
Theriva Biologics Announces Publication Of Clinical, Translational Results From VCN-01's Phase 1 Clinical Trial In Head & Neck Squamous Cell Carcinoma In Clinical Cancer Research JournalBenzinga · Jun 11, 2026, 12:43 PM
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer ResearchGlobenewswire Inc · Jun 11, 2026, 12:15 PM